Cargando…
Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy
Background: Selective serotonin reuptake inhibitors are a very common choice of antidepressive drug-therapy during pregnancy. In up to 30% of cases, they have been found to cause neonatal abstinence syndrome in newborn infants. Although often both time-limiting and self-limiting, severe symptoms of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313667/ https://www.ncbi.nlm.nih.gov/pubmed/30360382 http://dx.doi.org/10.3390/medicines5040113 |
_version_ | 1783383986024742912 |
---|---|
author | Pocivalnik, Mirjam Danda, Manfred Urlesberger, Berndt Raith, Wolfgang |
author_facet | Pocivalnik, Mirjam Danda, Manfred Urlesberger, Berndt Raith, Wolfgang |
author_sort | Pocivalnik, Mirjam |
collection | PubMed |
description | Background: Selective serotonin reuptake inhibitors are a very common choice of antidepressive drug-therapy during pregnancy. In up to 30% of cases, they have been found to cause neonatal abstinence syndrome in newborn infants. Although often both time-limiting and self-limiting, severe symptoms of neonatal abstinence syndrome (NAS) can occur. Methods/Results: We report a term male infant suffering from a severe brief resolved unexplained event caused by his mother’s sertraline intake during pregnancy. Conclusions: Newborn infants exposed to selective serotonine reuptake inhibitors (SSRIs) during pregnancy should be evaluated very carefully concerning NAS and monitored for NAS symptoms for a minimum of 72–96 h, or until symptoms have fully recovered using standardized protocols. There is a risk of severe NAS symptoms which might occur, and this circumstance should be discussed with the parents and taken into account before administering the drug. |
format | Online Article Text |
id | pubmed-6313667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63136672019-01-07 Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy Pocivalnik, Mirjam Danda, Manfred Urlesberger, Berndt Raith, Wolfgang Medicines (Basel) Case Report Background: Selective serotonin reuptake inhibitors are a very common choice of antidepressive drug-therapy during pregnancy. In up to 30% of cases, they have been found to cause neonatal abstinence syndrome in newborn infants. Although often both time-limiting and self-limiting, severe symptoms of neonatal abstinence syndrome (NAS) can occur. Methods/Results: We report a term male infant suffering from a severe brief resolved unexplained event caused by his mother’s sertraline intake during pregnancy. Conclusions: Newborn infants exposed to selective serotonine reuptake inhibitors (SSRIs) during pregnancy should be evaluated very carefully concerning NAS and monitored for NAS symptoms for a minimum of 72–96 h, or until symptoms have fully recovered using standardized protocols. There is a risk of severe NAS symptoms which might occur, and this circumstance should be discussed with the parents and taken into account before administering the drug. MDPI 2018-10-22 /pmc/articles/PMC6313667/ /pubmed/30360382 http://dx.doi.org/10.3390/medicines5040113 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Pocivalnik, Mirjam Danda, Manfred Urlesberger, Berndt Raith, Wolfgang Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy |
title | Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy |
title_full | Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy |
title_fullStr | Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy |
title_full_unstemmed | Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy |
title_short | Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy |
title_sort | severe brief resolved unexplained event in a newborn infant in association with maternal sertralin treatment during pregnancy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313667/ https://www.ncbi.nlm.nih.gov/pubmed/30360382 http://dx.doi.org/10.3390/medicines5040113 |
work_keys_str_mv | AT pocivalnikmirjam severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy AT dandamanfred severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy AT urlesbergerberndt severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy AT raithwolfgang severebriefresolvedunexplainedeventinanewborninfantinassociationwithmaternalsertralintreatmentduringpregnancy |